Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis

Journal of Infectious Diseases

Volumn 197, Issue 11, 2008, Pages 1519-1522

  Grandgirard, Denis ^a   Loeffler, Jutta M ^b   Fischetti, Vincent A ^b   Leib, Stephen L ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b ROCKEFELLER UNIVERSITY   (United States)

^c Institute for Infectious Diseases   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CPL 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL MENINGITIS; BACTERIOPHAGE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; NONHUMAN; OTITIS MEDIA; PNEUMONIA; PRIORITY JOURNAL; RAT; SINUSITIS; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; CEREBROSPINAL FLUID; COLONY COUNT, MICROBIAL; ENZYMES; HUMANS; INJECTIONS, INTRAPERITONEAL; MENINGITIS, PNEUMOCOCCAL; RATS; RATS, WISTAR; STREPTOCOCCUS PNEUMONIAE; VIRAL PROTEINS;

EID: 43949128054     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/587942     Document Type: Article

References (15)

1. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997; 337:970-6.
2. Lebel MH, McCracken GH Jr. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics 1989; 83:161-7.
3. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297:1784-92.
4. Jado I, Lopez R, Garcia E, Fenoll A, Casal J, Garcia P. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 2003; 52:967-73.
5. Loeffler JM, Fischetti VA. Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains. Antimicrob Agents Chemother 2003; 47:375-7.
6. Loeffler JM, Djurkovic S, Fischetti VA. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 2003; 71:6199-204.
7. Ronda C, Lopez R, Garcia E. Isolation and characterization of a new bacteriophage, Cp-1, infecting Streptococcus pneumoniae. J Virol 1981; 40:551-9.
8. Garcia JL, Garcia E, Arraras A, Garcia P, Ronda C, Lopez R. Cloning, purification, and biochemical characterization of the pneumococcal bacteriophage Cp-1 lysin. J Virol 1987; 61:2573-80.
9. Djurkovic S, Loeffler JM, Fischetti VA. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob Agents Chemother 2005; 49:1225-8.
10. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 2005; 49:4789-92.
11. McCullers JA, Karlstrom A, Iverson AR, Loeffler JM, Fischetti VA. Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog 2007; 3:e28.
12. Grandgirard D, Schurch C, Cottagnoud P, Leib SL. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2007; 51:2173-8.
13. Bifrare YD, Kummer J, Joss P, Täuber MG, Leib SL. Brain-derived neurotrophic factor protects against multiple forms of brain injury in bacterial meningitis. J Infect Dis 2005; 191:40-5.
14. Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 1995; 377:435-8.
15. Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001; 294:2170-2.